Medix Biochemica has completed the acquisition of Lee Biosolutions

PRESS RELEASE 27.11.2019

 Medix Biochemica has completed the acquisition of Lee Biosolutions, a leading provider of a large variety of high-quality biomaterials for the in vitro diagnostics industry. The news about the acquisition was originally announced on 18 November 2019. The acquisition expands Medix Biochemica’s leading portfolio of bioreagents as well as provides Medix Biochemica with a strong platform for further growth in the US market. Following the transaction, Lee Biosolutions forms a Center of Excellence focused on biomaterials for the IVD industry within Medix Biochemica’s group structure. President and COO of Lee Biosolutions, Matthew Lee, heads its operations and reports to the CEO of Medix Biochemica. CEO and Chairman of the Board of Lee Biosolutions, Burton Lee, will continue as Senior Advisor over a transition period and has become a shareholder in Medix Biochemica as part of the transaction.

 For more information:

Ann-Christine Sundell, Chairman of the Board of Medix Biochemica
Mobile: +358 40 536 7703
Email: ac.sundell@parnet.fi

Read more about Medix Biochemica and Lee Biosolutions: